Relationship between low T3 syndrome and NT-proBNP levels in non-cardiac patients

Acta Cardiologica

Volumn 62, Issue 1, 2007, Pages 19-24

  Pinelli, Massimiliano ^a   Bindi, Massimo ^a,b   Cassetti, Giuseppina ^a   Moroni, Federica ^a   Pandolfo, Claudia ^a   Rosada, Javier ^a   Castiglioni, Maido ^a  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

^b NONE   (Italy)

Author keywords

Cardiac dysfunction; Heart failure; NT proBNP; Thyroid hormone

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; LIOTHYRONINE;

AGED; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DEMOGRAPHY; DIASTOLIC DYSFUNCTION; EUTHYROID SICK SYNDROME; FEMALE; FREE LIOTHYRONINE INDEX; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART HEMODYNAMICS; HUMAN; LIOTHYRONINE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; THYROID FUNCTION TEST;

AGED; DISEASE PROGRESSION; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES; TRIIODOTHYRONINE;

EID: 33847642840     PISSN: 00015385     EISSN: None     Source Type: Journal    
DOI: 10.2143/AC.62.1.2019366     Document Type: Article

References (40)

1. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med 2001; 344: 501-9.
2. Wartofsky L, Burman KD. Alterations in thyroid function in patients with systemic illness: the "euthyroid sick syndrome". Endocr Rev 1982; 3: 164-216.
3. De Groot LJ. Dangerous dogmas in medicine: the nonthyroidal illness syndrome. J Clin Endocr Metab 1999; 84: 151-64.
4. Iervasi G, Pingitore A, Landi P, Raciti M, Ripoli A, Scarlattini M, L'Abbate A, Donate L. Low-T3 syndrome: a strong prognostic predictor of death in patients with heart disease. Circulation 2003; 107: 708-13.
5. Pingitore A, Landi P, Taddei MC, Ripoli A, L'Abbate A, lervasi G. Triiodothyronine levels for risk stratification of patients with chronic heart failure. Am J Med 2005; 118: 132-6.
6. Shanoudy H, Soliman A, Moe S, Hadian D, Veldhuis JD, Iranmanesh A, Russel DC. Early manifestation of 'sick euthyroid' syndrome in patients with compensated chronic heart failure. J Card Fail 2001; 7: 146-52.
7. Lainchbury JG, Campbell E, Frampton CM, Yandle TG, Nicholls MG, Richards AM. Brain natriuretic peptide and n-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J Am Coll Cardiol 2003; 42: 728-35.
8. Tsutamoto T, Wada A, Moeda K, Hisanaga T, Maeda Y, Fukai D, Ohnishi M, Sugimoto Y, Kinoshima M. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997; 96: 509-16.
9. Hartmann F, Packer M, Coats AJ, Fowler MB, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne D, Anker SD, Amann-Zalan I, Hoersch S, Katus HA. Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Circulation 2004; 110: 1780-6.
10. Murdoch DR, McDonagh TA, Byrne J, Blue L, Farmer R, Morton JJ, Dargie HJ. Titration of vasodilatator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. Am Heart J 1999; 138: 1126-32.
11. Richards AM, Troughton R, Lainchbury J, Doughty R, Wright S. Guiding and monitoring of heart failure therapy with NT-proBNP: concepts and clinical studies. J Card Fail 2005; 11 (5 suppl): S34-7.
12. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr. Plasma brain natriuretic peptide to detect preclinical ventricular systolic or diastolic dysfunction. A community-based study. Circulation 2004; 109: 3176-81.
13. Mark DB, Felker GM. B-type natriuretic peptide - A biomarker for all seasons? N Engl J Med 2004; 350: 718-20.
14. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1-S266.
15. Feldman T, Borow KM, Sarne DH, Neumann A, Lang RM. Myocardial mechanics in hyperthyroidism: importance of left ventricular loading conditions, heart rate and contractile state. J Am Coll Cardiol 1986; 7: 967-74.
16. th edition. Philadelphia, PA: Lippincott Williams & Wilkins, 2000: 777-82.
17. Ripoli A, Pingitore A, Favilli B, Bottoni A, Turchi S, Osman NF, De Marchi D, Lombardi M, L'Abbate A, Iervasi G. Does subclinical hypothyroidism affect cardiac pump performance? J Am Coll Cardiol 2005; 45: 439-45.
18. Friberg L, Werner S, Eggertsen G, Ahnve S. Rapid down-regulation of thyroid hormones in acute myocardial infarction: is it cardioprotective in patients with angina? Arch Intern Med 2002; 162: 1388-94.
19. Holland FW, Brown PS Jr, Weintraub BD, Clark RE. Cardiopulmonary bypass and thyroid function: a "euthyroid sick sindrome". Ann Thorac Surg 1991; 52: 46-50.
20. Camacho PM, Dwarkanathan AA. Sick euthyroid syndrome. What to do when thyroid function tests are abnormal in critically ill patients. Postgrad Med 1999; 105: 215-9.
21. Hamilton MA, Stevenson LW, Luu M, Walden JA. Altered thyroid hormone metabolism in advanced heart failure. J Am Coll Cardiol 1990; 16: 91-5.
22. Ascheim DD, Hryniewicz K. Thyroid hormone metabolism in patients with congestive heart failure: the low triiodothyronine state. Thyroid 2002; 12: 511-5.
23. Raymond I, Groenning BA, Hildebrandt PR, Nilsson JC, Baumann M, Trawinski J, Pedersen F. The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population. Heart 2003; 89: 745-51.
24. Krauser DG, Lloyd-Jones DM, Chae CU, Cameron R, Anwaruddin S, Baggish AL, Chen A, Tung R, Januzzi JL Jr. Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: a ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy. Am Heart J 2005; 149: 744-50.
25. Willis MS, Lee ES, Grenache DG. Effect of anemia on plasma concentrations of NT-proBNP. Clin Chim Acta 2005; 358: 175-81.
26. Vickery S, Price CP, John RI, Abbas NA, Webb MC, Kempson ME, Lamb EJ. B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: relationship to renal function and left ventricular hypertrophy. Am J Kidney Dis 2005; 46: 610-20.
27. Raizada V, Thakore K, Luo W, McGuire PG. Cardiac chamber-specific alterations of ANP and BNP expression with advancing age and with systemic hypertension. Mol Cell Biochem 2001; 16: 137-40.
28. Clark BA, Elahi D, Shannon RP, Wei JY, Epstein FH. Influence of age and dose on the end-organ responses to atrial natriuretic peptide in humans. Am J Hypert ens 1991; 4: 500-7.
29. Muscari A, Berzigotti A, Bianchi G, Giannoni C, Ligabue A, Magalotti D, Sbano D, Zacchini A, Zoli M. Non-cardiac determinants of NT-proBNP levels in the elderly: Relevance of haematocrit and hepatic steatosis. Eur J Heart Fail 2006; 5: 468-76.
30. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, Wolf PA, Vasan RS. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004; 350: 655-63.
31. Magnusson M, Melander O, Israelsson B, Grubb A, Groop L, Jovinge S. Elevated plasma levels of NT-proBNP in patients with type 2 diabetes without overt cardiovascular disease. Diabetes Care 2004; 27: 1929-35.
32. Lubien E, De Maria A, Krishnaswamy P, Clopton P, Koon J, Kazanegra R, Garretto N, Wanner E, Maisel AS. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation 2002; 105: 595-601.
33. Yamaguchi H, Yoshida J, Yamamoto K, Sakata Y, Mano T, Akehi N, Hori M, Lim YJ, Mishima M, Masuyama T. Elevation of plasma brain natriuretic peptide is a hallmark of diastolic heart failure independent of ventricular hypertrophy. J Am Coll Cardiol 2004; 43: 55-60.
34. Katzeff HL, Powell SR, Ojamaa K. Alterations in cardiac contractility and gene expression during low-T3 syndrome: prevention with T3. Am J Physiol 1997; 273: E951-E956.
35. 2+)I of human cardiomyocytes in culture. Cardiovasc Res 2001; 51: 322-30.
36. Slag MF, Morley JE, Elson MK, Crowson TW, Nuttal FQ, Shafer RB. Hypothyroxinemia in critically ill patients as a predictor of high mortality. JAMA 1981; 245: 43-5.
37. Sumita S, Ujike Y, Namiki A, Watanabe H, Kawamata M, Watanabe A, Satoh O. Suppression of the thyrotropin response to thyrotropin-releasing hormone and its association with severity of critical illness. Crit Care Med 1994; 22: 1603-9.
38. Schultz M, Faber J, Kistorp C, Jarlov A, Pedersen F, Wiinberg N, Hildebrandt P. N-terminal-pro-B-type natriuretic peptide (NT-pro-BNP) in different thyroid function states. Clin Endocrinol (Oxf) 2004; 60: 54-9.
39. Hamilton MA, Stevenson LW, Fonarow GC. Safety and hemodynamic effects of intravenous triiodothyronine in advanced congestive heart failure. Am J Cardiol 1998; 81: 443-7.
40. Mullis-Jansson SL, Argenziano M, Corwin S, Homma S, Weinberg AD, Williams M, Rose EA, Smith CR. A randomized double-blind study of the effect of triiodothyronine on cardiac function and morbidity after coronary bypass surgery. J Thorac Cardiovasc Surg 1999; 117: 1128-34.